International Journal of Applied Pharmaceutical Sciences and Research

Analytical Separation and Characterisation of Degradation Products and the Development and Validation of a Stability-Indicating Method for the Estimation of Impurities in Montelukast Oral Dosage Formulation

Anas Rasheed*[1], Dr. Osman Ahmed[2]

1. Research Scholar, Faculty of Pharmacy, Pacific Academy of Higher Education and Research University, Udaipur.
2. Research Supervisor, Faculty of Pharmacy, Pacific Academy of Higher Education and Research University, Udaipur.

Corresponding Author:
Anas Rasheed,
Research Scholar, Faculty of Pharmacy,
Pacific Academy of Higher Education and Research University, Udaipur.
E-mail: anasrasheed6500@gmail.com

Abstract:

A short selective, precise, accurate and sensitive stability-indicating gradient LC-MS/MS^n method was developed for the quantitative determination of process-related impurities and degradation products of Montelukast in pharmaceutical oral dosage formulations. During the stress study, the degradation products of Montelukast were well-resolved from Montelukast and its impurities and the mass balances were found to be satisfactory in all the stress conditions, thus proving the stability-indicating capability of the method. The developed method was validated as per ICH guidelines with respect to specificity, linearity, limit of detection and quantification, accuracy, precision, ruggedness, and robustness. During the stability analysis of the drug product, one unknown impurity was detected by the above stability-indicating method. The flow rate was 0.5 ml/min and effluent was monitored at 226nm. Retention time was found to be 7.836±0.012 min. The LOD and LOQ values were found to be 0.2099 (μg/ml) and 0.6362 (μg/ml) respectively.

1. Introduction

Montelukast is a leukotriene receptor antagonist (LTRA) used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies. Montelukast blocks the action of leukotriene D4 on the cysteinyl leukotriene receptor CysLT1 in the lungs and bronchial tubes by binding to it. This reduces the bronchoconstriction otherwise caused by the leukotriene, and results in less inflammation. Because of its method of operation, it is not useful for the treatment of acute asthma attacks. Chemically it is, 2-[1-({[(1R)-1-{3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl] phenyl}-3- [2- (2-hydroxypropan-2-yl) phenyl] propyl]sulfanyl} methyl) cyclopropyl] acetic acid (Figure 1).

Chemical stability of Montelukast is a matter of great concern as it affects the safety and efficacy of the finished drug product. Forced degradation studies provide data to support identification of possible degradants; degradation pathways and intrinsic stability of the Montelukast molecule and validation of stability indicating analytical procedures.(ICH Q2 (R1), 2005)

A detailed literature revealed that several analytical methods have been reported for the determination of Montelukast in pharmaceutical oral dosage forms.(Arayne MS et al., 2009, Pourghazi K et al., 2011, Rote A et al., 2011) In our present knowledge, there is no method reported for the estimation forced degradationstudies of Montelukast in pharmaceutical oral dosage form by UPLC. (Michael E Swartz, 2005)

As per the stringent regulatory requirements recommended by the ICH and regulatory agencies, it is mandatory and important to identify and structurally characterize any impurity formed during production and stability testing, exceeding the identification threshold. Various analytical instruments and advanced hyphenated techniques are routinely used to carry out the impurity profile study.

Figure 1: Molecular Structure of Montelukast

The present work aims with the development of a method to separate the degradation product by preparative UPLC and subjected to ESI-MS/MS. The present study describes the separation of different impurities of Montelukast, as well as the development and validation of a stability-indicating RP-UPLC method for the estimation of degradation and process-related impurities of Montelukast. Forced degradation studies were performed on the drug product to show the stability-indicating nature of the method. These studies were performed in accordance with established ICH guidelines.

2. Experimental

2.1 Materials
Montelukast (98.60 % purity) used as analytical standard was procured from Spectrum Labs (Hyderabad).

HPLC grade methanol, Acetonitrile (HPLC grade) was purchased from Qualigens fine chemicals, Mumbai, India. Distilled, 0.45 μm filtered water used for UPLC quantification and preparation of buffer. Buffers and all other chemicals were analytical grade. The oral dosage (MONTEMAC) labeled to contain each 10 mg of Montelukast. All chemicals used were of pharmaceutical or special analytical grade.

2.2 Instrumentation
Acquity, Waters UPLC system consisting of a Water 2695 binary gradient pump, an inbuilt auto sampler, a column oven and Water 2996 wavelength absorbance detector (PDA) was employed throughout the analysis.

The data was collected using Empower 2 software. The column used was Hypersil BDS C18 (100 mm x 2.1 mm, 1.7 μm). A Band line sonerexsonicator was used for enhancing dissolution of the compounds. A Labindia pH System 362 was used for pH adjustment.

The electrospray ionization and MS-MS studies were performed on the triple quadrupole mass spectrometer PE Sciex Model: API 3000.

2.3 Chromatographic conditions

Table 1: Chromatographic Conditions of the validating method

Parameter	Value
Column	Hypersil BDS C18 (100 mm x 2.1 mm, 1.7 μm)
Mobile Phase	Acetonitrile and Methanol in the ratio of 68:32%v/v
Flow rate	0.5mL/min
Run time	14 Min.
Column Temperature	Maintained at ambient temperature
Injection volume	5 μL
Detection wavelength	226nm
Diluent	Mobile Phase

2.4 Preparation of Standard Stock Solution

2.4.1 Preparation of Diluent:
In order to achieve the separation under the optimized conditions after experimental trials that can be summarized. Stationary phase like Hypersil BDS C18 (100 mm x 2.1 mm, 1.7 μm) column was most suitable one, since it produced symmetrical peaks with high resolution, very good sensitivity and good resolution. The flow rate was maintained 0.5 mL min-1 shows good resolution. The PDA detector response of Montelukast was studied and the best wavelength was found to be 226 nm showing highest sensitivity.

The mixture of two solutions Acetonitrile and Methanol in the ratio of 68:32%v/v with gradient programming was used as mobile phase at 0.5mL/min which was found to be an appropriate mobile phase for separation of Montelukast. The column was maintained at ambient temperature.

2.4.2 Preparation of internal standard solution
Weighed accurately about 10 mg of Quinine sulphate working standard and transfer to 100 ml volumetric flask, add 50 ml of mobile phase and sonicate to dissolve it completely and then volume was made up to the mark with mobile phase to get 100 μg/ml of standard stock solution of working standard. Then it was ultrasonicated for 10 minutes and filtered through 0.20 μ membrane filter.

2.4.3 Preparation of Montelukast standard solution:
Weighed accurately about 10 mg of Montelukast and transfer to 100 ml volumetric flask, add 50 ml of mobile

phase and sonicate to dissolve it completely and then volume was made up to the mark with mobile phase to get 100 µg/ml of standard stock solution of working standard. Then it was ultrasonicated for 10 minutes and filtered through 0.20 µ membrane filter. Linearity was determined in the range of 2- 10 µg mL-1.

2.5 Stability Indicating Studies
Stability Indicating studies like acid hydrolysis, basic hydrolysis, wet heat degradation and oxidative degradation were carried out.

2.6 Mass Spectrometry Conditions for MS/MS
The samples (5 µL) is injected directly into the source by the flow injection method using Acetonitrile and Methanol in the ratio of 68:32%v/v as mobile phase at a flow rate of 0.5 mL/min. The mass spectra were recorded in ESI negative mode. Ultra-high purity nitrogen and helium were used as curtain and collision gas, respectively. The typical ion source conditions were: nebulizer gas, 60 psi; dry temperature, 325˚C; dry gas, 5.0 mL/min; capillary voltage, 5kV; capillary current, 80.243 nA; vapourizer temperature, 400°C; dwell time, 200 ms. For the collision-induced dissociation (CID) experiments, the precursor ion was selected using the quadrapole analyzer and product ions were analyzed by the time-of-flight analyzer. HRMS data acquisition was performed by the following source conditions: capillary voltage, 5 kV; declustering potential (DP) and collision energy (CE) were −60 V and −10 V, respectively; focusing potential, 220 V; resolution 40,000 (FWHM).

3. Results and discussions

3.1 Validation
The analytical method was validated with respect to parameters such as linearity, precision, specificity and accuracy, limit of detection (LOD), limit of quantitation (LOQ) and robustness in compliance with ICH guidelines.

3.2 Linearity and range:
The linearity of an analytical procedure is the ability to obtain test results that are directly proportional to the concentration of an analyte in the sample.

The calibration curve showed good linearity in the range of 2 – 10 µg/ml, for Montelukast (API) with correlation coefficient (r2) of 0.9968. A typical calibration curve has the regression equation of y = 25465.15x +260382.3for Montelukast. Results are given in Table 2.

**Figure 2:** Standard Chromatogram of Montelukast, using mobile phase of Acetonitrile and Methanol in the ratio of 68:32%v/v

Figure 3: Calibration curve of Montelukast

3.3 Limit of Detection (LOD) and Limit of Quantitation (LOQ)

The LOD and LOQ of Montelukast were calculated by mathematical equation. LOD= 3.3×standard deviation ÷ slope and LOQ=10×standard deviation ÷ slope. The LOD of Montelukast was found to be 0.2099 (μg/ml) and the LOQ of Montelukast was found to be 0.6362 (μg/ml). Results are given in Table 2.

3.4 Precision:

The precision of the method was studied in terms of intraday and interday precision of sample injections (4 μg/ml). Intraday precision was investigated by injecting six replicate samples of each of the sample on the same day. The % RSD was found to be 0.32%. Interday precision was assessed by analysis of the 6 solutions on three consecutive days. The % RSD obtained was found to be 0.30%%. Low % RSD values indicate that the method is precise. The results are given in Table 3.

3.5 Accuracy:

To study the accuracy of method, recovery studies were carried out by spiking of standard drug solution to pre-analyzed sample at three different levels i.e., at 50, 100, and 150%. The resultant solutions were then reanalyzed by the proposed method. At each level of the amount, six determinations were performed. From the data obtained, the method was found to be accurate. The % recovery and %RSD were calculated and presented in Table 4.

3.6 Robustness:

Small deliberate changes in chromatographic conditions such as change in temperature (± 2°C), flow rate (± 0.1ml/min) and wavelength of detection (±2nm) were studied to determine the robustness of the method. The results were in favor of (% RSD < 2%) the developed UPLC method for the analysis of Montelukast. The results are given in Table 5.

3.7 Results of Stability Indicating Studies

According to Singh and Bakshi, 2000, the stress testing suggests a target degradation of 20-80 % for establishing stability indicating nature of the method. UPLC study of samples obtained on stress testing of Montelukast under different conditions using mixture Acetonitrile and Methanol in the ratio of 68:32%v/v as a mobile solvent system suggested the following degradation behaviour.

3.7.1 Acid hydrolysis:

An accurate 10 ml of pure drug sample solution was transferred to a clean and dry round bottom flask (RBF). 30 ml of 0.1 N HCl was added to it. It was refluxed in a water bath at 60°C for 4 hours. Drug became soluble after reflux which was insoluble initially. Allowed to cool at room temperature. The sample was then neutralized using 2N NaOH solution and final volume of the sample was made up to 100ml with water to prepare 100ppm solution. It was injected into the UPLC system against a blank of Acetonitrile and Methanol in the ratio of 68:32%v/v after optimizing the mobile phase composition, chromatogram was recorded and shown in Figure 4.

3.7.2. Basic hydrolysis:

An accurate 10 ml of pure drug sample solution was transferred to a clean and dry RBF. 30 ml of 0.1N NaOH was added to it. It was refluxed in a water bath at 60°C for 4 hours. Drug became soluble after reflux which was insoluble initially. It was allowed to cool at room temperature. The sample was then neutralized using 2N HCl solution and final volume of the sample was made up to 100ml with water to prepare 100ppm solution. It was injected into the UPLC system against a blank of Acetonitrile and Methanol in the ratio of 68:32%v/v after optimizing the mobile phase composition, chromatogram was recorded and shown in Figure 5.

3.7.3 Wet heat degradation

Accurate 10 ml of pure drug sample was transferred to a clean and dry RBF. 30 ml of HPLC grade water was added to it. Then, it was refluxed in a water bath at 60°C for 6 hours uninterruptedly. After the completion of reflux, the drug became soluble and the mixture of drug and water was allowed to cool at room temperature. Final volume was made up to 100 ml with HPLC grade water to prepare 100 ppm solution. It was injected into the UPLC system against a blank of Acetonitrile and Methanol in the ratio of 68:32%v/v after optimizing the mobile phase composition, chromatogram was recorded and shown in Figure. 6.

3.7.4 Oxidation with (3%) H_2O_2

Approximately 10 ml of pure drug sample was transferred in a clean and dry 100 ml volumetric flask. 30 ml of 3% H_2O_2 and a little methanol was added to it to make it soluble and then kept as such in dark for 24 hours. Final volume was made up to 100 ml using water to prepare 100 ppm solution. The above sample was injected into the UPLC system. The chromatogram was recorded and shown in Figure 7.

In all degradation studies, there was a significant formation of degradation products when compared to that of a standard. This indicates that, the drug may be degraded to low molecular weight non-chromophoric compounds.

3.7.5 Structure and Separation of the Known/ Unknown Impurities

An unknown impurity with a relative retention time (RRT) of 1.396 with respect to Montelukast was observed during the stability study of the drug product and we tried to enhance the impurity by using the forced degradations to separate it. But the impurity was not increased in any trial. So the impurity was separated by preparative UPLC from stability samples with a purity of

> 98% and used for its characterisation by LC-MS -MS^n studies.

The positive ESI-MS spectrum of the unknown impurity showed a peak at m/z 612.24 amu [M+H]+ (Figure 8) which was 26.22 amu higher than that of Montelukast (m/z 586.02). The comparison of MS/MS studies of the unknown impurity and Montelukast showed common fragment ions at m/z 590.58. The common fragment ion peak suggests that 7-chloroquinolin-2-yl was intact and changes were at the sulfanylmethyl- cyclopropyl - acetic atom.

3.8 Impurity profile

The impurity profile shows us the amount of respective impurities obtained in the studied formulations.

Table 2: Summary of validation parameters for the proposed method

Parameter	Montelukast
Linearity	2 – 10 µg/ml
Intercept (c)	260382.3
Slope (m)	25465.15
Correlation coefficient	0.9968
LOD	0.2099 (µg/ml)
LOQ	0.6362 (µg/ml)

Table 3: Results of precision studies

Replicate		Montelukast	
S.No.	Concentration Taken (µg/ml)	Area	%LC
1		363431	99.98%
2		363486	99.97%
3	04.00	363393	99.99%
4		363434	99.98%
5		363452	99.98%
6		363391	99.99%
Average			99.98%
Std.Dev			0.00752
% RSD			0.01%
Standard weight			4mcg
Standard potency			98.60%

Table 4: Results of accuracy study

Montelukast						
Level %	Amount added (µg/ml)	Amount found (µg/ml)	% Recovery	Mean recovery (%)	Std.Dev	% RSD
50	02.25	02.23	99.11	99.39%	0.24846	0.25%
100	04.50	04.48	99.53			
150	06.75	06.72	99.55			

Table 5: Results of Robustness Studies

| Robustness Studies			
Parameter	Value	Peak Area	% RSD
Flow Rate	Low	364739	
	Actual	365312	0.12%
	Plus	365589	
Temperature	Low	364864	
	Actual	365039	0.05%
	Plus	365245	
Wavelength	Low	364934	
	Actual	365477	0.14%
	Plus	365973	

Figure 4: Chromatogram showing the degraded products in Acidic degradation

75

**Figure 5:** Chromatogram showing the degraded products in Basic degradation

**Figure 6:** Chromatogram showing the degraded products in Wet heat degradation

Figure 7: Chromatogram showing the degraded products in H_2O_2

**Table 6:** Stability indicating study for the developed method

Nature of Stress	Degradation condition	Time(h)	Number of degradation products (Rt)
Acidic	60°C	3	2 (4.712, 7.206)
Basic	60°C	9	1 (8.994)
Oxidative	RT	48	1 (1.129)
Wet Heat	105°C	24	1 (9.247)

Table 7: Impurity Profile of Montelukast

S.no	Impurity name	Active pharmaceutical ingredient	Relative retention time
1	Impurity-A1	Montelukast	2.762
2	Impurity-A2		2.491
3	Impurity-B		1.692
4	Impurity-C		0.860
5	Any individual unknown impurity		1.396

Table 8: Compositions of Montelukast in MS/MS spectra

Analyte	Observed ion mass (Da)	Proposed formula	Calculated mass (Da)	Error (ppm)
Montelukast	586.02	$C_{35}H_{36}ClNO_3S$	586.01	1.34
	575.46	$C_{35}H_{37}ClN_2O_2S$	575.35	2.49
	568.38	$C_{35}H_{36}ClNO_2S$	568.22	-2.73
	540.63	$C_{35}H_{34}ClNO_2S$	540.59	-1.17
	472.71	$C_{35}H_{36}ClNO_4S$	472.64	-2.12
	612.24	$C_{35}H_{35}ClNNaO_2S$	612.19	1.26

**Figure. 8:** Chromatogram showing the impurities of Montelukast

Figure 9: MS/MS^n characterisation of impurities in Montelukast

4. Conclusion

This research paper describes the separation and characterization of impurities in Montelukast pharmaceutical oral dosage formulations. The impurities were isolated by preparative liquid chromatography and characterized by using spectroscopic techniques. A simple and efficient RP-UPLC method development and validation were discussed. The degradatedproducts were formed during the study and was well-resolved from Montelukast by the proposed RP-UPLC method. The proposed structure of Montelukast was characterized by MS/MS^n analysis and was further confirmed to be accurate mass measurements.

Conflict of interest
None declared

5.References

1. Arayne MS, Sultana N, Hussain F (2009). Spectrophotometric method for quantitative determination of montelukast in bulk, pharmaceutical formulations and human serum. *J Anal Chem.* 64:69-05.

2. International Conference on Harmonization (2005) Guideline on Validation of Analytical Procedures Text and Methodology: Q2 (R1).

3. Michael E Swartz (2005). Ultra performance liquid chromatography UPLC: an introduction. *Separation science redefined.* 1:8-14.

4. Pourghazi K, Khoshhesab ZM, Golpayeganizadeh A, Shapouri MR, et al (2011). Spectrophotometric determination of cetirizine and montelukast in prepared formulations. *Int J Pharm Pharm Sci.* 3:128-30.

5. Rote A, Niphade V (2011). Determination of montelukast sodium and levocetirizinedihydrochloride in combined tablet dosage form by HPTLC and first-derivative spectrophotometry. *J LiqChromatogrRelat Technol.* 34:155-67.

6. S Singh, M Bakshi (2000), Guidance on conduct of: Stress tests to determine Inherent Stability of Drugs. *Pharmaceutical Technology On-line.* April 1-14.

How to cite this article:

Anas Rasheed, Dr. Osman Ahmed (2017).Analytical separation and characterization of degradation products and the development and validation of a stability indicating method for the estimation of impurities in montelukast oral dosage formulation.*Int J App Pharm Sci Res.* 2(3):69-77.http://dx.doi.org/10.21477/ijapsr.v2i03.8252.